Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
Latest in Cardiology from ACC.org
- Eagle’s Eye View: ACC Updated Expect Consensus Decision Pathway on HFpEFIn this week’s View, Dr. Eagle looks at a post-hoc analysis of the API-CAT trial that showed recurrent venous thromboembolism (VTE) is uncommon but associated with poor short-term survival of patients with cancer-associated thrombosis.
- Indexing Ascending Aortic Dimensions to Height vs. Absolute Diameter to Identify High-Risk PatientsIndexing ascending aortopathy (AA) to height better identifies patients, especially women, who could benefit from earlier surgery rather than absolute diameters, according to a recent study published in JACC: Advances.
- Higher TAVR Volume Associated With Lower Complications, Not Lower Failure to Rescue Rates | NCDR StudyHigher annualized TAVR volume is associated with lower complication rates but not with lower failure to rescue (FTR) rates, according to a recent study published in JACC: Cardiovascular Interventions.
- OPTIMA-AF: 1-Month vs. 12-Month Dual Antithrombotic Therapy Post PCIOnly one month of dual antithrombotic therapy followed by direct oral anticoagulant (DOAC) monotherapy proved to be noninferior in terms of efficacy and superior in terms of bleeding outcomes to the standard 12-month dual antithrombotic therapy post PCI among patients with atrial fibrillation (AFib), according to results of the OPTIMA-AF trial published July 15 in […]
- ACCEL Lite: Top Practice-Changing Advancements in Echocardiography Since ACC.25 In this interview, Steven E. Nissen MD, MACC David H. Wiener, MD, FACC discuss practice-changing advancements in echocardiography.